MapLight Therapeutics, Inc.
MPLT
NASDAQ·Healthcare·Biotechnology·Mkt cap $584.3M
$13.77
▲ +4.79%
P/E
-2.66
Mkt Cap
$584.3M
52-Wk Range
$9.10–$40.43
52-Week Range
$9.10 - $40.43
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 24.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary neural circuit identification platform enabling causal disease target validation
- Diversified clinical pipeline across multiple high-prevalence CNS disorders with significant unmet medical needs
- Strategic backing from Catalyst4, Inc. providing development resources and expertise
- Muscarinic agonist approach addressing treatment-resistant schizophrenia and psychosis indications with limited alternatives
Bear Case
1 risk
- High volatility (beta 2.6). Larger-than-normal price swings expected.
Growth
Stable outlook
Emerging player in Biotechnology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-53.3% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying MPLT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 18, 2026
AUG 13, 2026
Reported EPS of -$1.32 vs -$1.35 consensus (+2.2% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+2.2%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
9 analysts · 89% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
89%
Hold
11%
Sell
0%
Median Price Target
—
Latest: Needham · Aug 31, 2026
vs Industry
How MPLT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related